{"links":{"feed":"https://www.erudio.com/reports/cou-aa-302-nct00887198/feed.json","html":"https://www.erudio.com/reports/cou-aa-302-nct00887198","json":"https://www.erudio.com/reports/cou-aa-302-nct00887198.json","markdown":"https://www.erudio.com/reports/cou-aa-302-nct00887198.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"cou-aa-302-nct00887198"}},"request":"https://www.erudio.com/contact?report=cou-aa-302-nct00887198"},"offer":{"cited_clinicians":7,"cited_commentary_sources":22,"verified_hcp_statements":266,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":12},"for_sale":true,"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"cou-aa-302-nct00887198"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=cou-aa-302-nct00887198","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/cou-aa-302-nct00887198","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 266 verified statements · 19 from 7 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-14T11:30:43.253074Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Overall Survival"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Radiographic Progression-free Survival (rPFS)"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":17,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":25,"coverage":"discussed","id":"A1","source_count":5,"title":"First-line choice, comorbidity and patient burden"},{"claim_count":17,"coverage":"discussed","id":"A2","source_count":2,"title":"Prednisone's physiological and anticancer roles"},{"claim_count":13,"coverage":"discussed","id":"A3","source_count":6,"title":"Chemotherapy alternatives, treatment opportunity and cost"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":2,"title":"Prior local therapy and interpretation of subgroup associations"},{"claim_count":8,"coverage":"discussed","id":"A5","source_count":3,"title":"Exposure-defined pathways, progression and intolerance exceptions"},{"claim_count":5,"coverage":"discussed","id":"A7","source_count":3,"title":"Alternative combinations and regimen-specific bone protection"},{"claim_count":15,"coverage":"discussed","id":"A10","source_count":1,"title":"Development experience, exceptional response and predictive biology"}],"counts":{"beyond_population_findings":4,"beyond_population_statements":14,"cited_clinicians":7,"cited_clinicians_by_role":{"physician, Medical oncology":5,"physician, Radiation oncology":2},"cited_physicians":7,"cited_sources":37,"claims_by_expression_type":{"comparison":27,"experience":9,"interpretation":87,"opinion":44,"primary_context":38,"question":7,"restatement":23,"uncertainty":20,"unspecified":11},"claims_by_kind":{"objective_result":17,"protocol_statement":9,"publication_statement":112,"source_observation":128},"clinician_statements":19,"evidence_units":208,"findings":11,"organisational_accounts":2,"people_cited":17,"people_identity_verified":12,"people_total":18,"screened_sources":120,"verified_claims":266},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":23,"claims_by_group":{"comparisons":2,"experience":1,"questions":3,"restated":0,"views":17},"limitations":3,"links":{"context":6,"support":25},"ma_question":true,"named_voices":2,"passages":16,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"One speaker would probably favor enzalutamide for uncomplicated mCRPC, while preserving reasons to consider abiraterone"},{"cited_clinicians":0,"id":"F2","structure":{"claims":13,"claims_by_group":{"comparisons":4,"experience":0,"questions":1,"restated":1,"views":7},"limitations":2,"links":{"context":2,"support":17},"ma_question":true,"named_voices":1,"passages":10,"sources":2,"sources_by_kind":{"media":2}},"title":"One speaker reads cross-trial results as numerically favoring enzalutamide over abiraterone; commentary weighs population, endpoint, steroid-control and crossover caveats."},{"cited_clinicians":4,"id":"F3","structure":{"claims":20,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":8,"views":9},"limitations":2,"links":{"context":2,"support":24},"ma_question":true,"named_voices":4,"passages":19,"sources":7,"sources_by_kind":{"commentary":2,"media":3,"publication":2}},"title":"Speakers regard pre-chemotherapy abiraterone as a major advance, but differ in how strongly they describe its survival value"},{"cited_clinicians":2,"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":6,"views":4},"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":4,"passages":12,"sources":8,"sources_by_kind":{"commentary":3,"media":2,"publication":3}},"title":"Speakers give symptom control and chemotherapy deferral substantial clinical weight"},{"cited_clinicians":0,"id":"F5","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":1,"questions":6,"restated":4,"views":4},"limitations":2,"links":{"context":0,"support":22},"ma_question":true,"named_voices":0,"passages":8,"sources":3,"sources_by_kind":{"media":2,"publication":1}},"title":"Whether reducing prednisone improves the abiraterone trade-off remains an open question in one podcast exchange"},{"cited_clinicians":0,"id":"F6","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":6,"views":7},"limitations":2,"links":{"context":1,"support":20},"ma_question":true,"named_voices":1,"passages":13,"sources":6,"sources_by_kind":{"media":3,"publication":3}},"title":"One safety interview offers strong long-term reassurance, while other discussions emphasize patient-specific risks"},{"cited_clinicians":3,"id":"F7","structure":{"claims":12,"claims_by_group":{"comparisons":3,"experience":2,"questions":0,"restated":4,"views":3},"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":3,"passages":10,"sources":6,"sources_by_kind":{"commentary":2,"media":4}},"title":"Speakers see oral abiraterone as widening treatment opportunity; one X account questions the cost of earlier use"},{"cited_clinicians":1,"id":"F8","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":4},"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":6,"sources":3,"sources_by_kind":{"commentary":3}},"title":"One X account finds prior-local-therapy analyses reassuring, but not evidence of a causal survival gain"},{"cited_clinicians":1,"id":"F9","structure":{"claims":22,"claims_by_group":{"comparisons":2,"experience":0,"questions":5,"restated":2,"views":13},"limitations":2,"links":{"context":3,"support":23},"ma_question":true,"named_voices":2,"passages":16,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"A podcast speaker and an X account discourage serial ARPI use; the episode separates intolerance from progression"},{"cited_clinicians":1,"id":"F11","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":3},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"One speaker favors enzalutamide–radium-223, while one X account relays no OS benefit for a different intensification approach"},{"cited_clinicians":0,"id":"F14","structure":{"claims":20,"claims_by_group":{"comparisons":2,"experience":5,"questions":0,"restated":6,"views":7},"limitations":2,"links":{"context":1,"support":27},"ma_question":true,"named_voices":0,"passages":15,"sources":2,"sources_by_kind":{"media":1,"publication":1}},"title":"A discussion weighs androgen biology, one prolonged abiraterone response and unvalidated selection hypotheses; a publication reports benefit across ERG groups without statistically significant differential benefit."}],"open_question":{"basis":"From finding F1 (23 statements from 2 speakers in 5 sources)","cited_claim_ids":["claim-33ef6f0db4b3eb151df2","claim-d8aa6b4844161261402d","claim-bea6f69a79c553950838","claim-e5e9e65d0c07a1d11443","claim-1298ea29e1107808d855","claim-a6a3bcfb73ef8e84ae80","claim-a114e625c7c45b31818d","claim-fb3b297502e6252d0f2b","claim-f83a2b19a4c0c61fc73d","claim-199c652eadaa6deeb2e0","claim-e02522f0b69886805952","claim-00d3969ae57f89397c61","claim-70077fe19d3a2dbad86d","claim-14087ae940ed7e6498a2","claim-b8a535ba7a81d66df76c"],"finding_ids":["F1"],"question":"What clinical or biological features do clinicians say could guide choosing abiraterone acetate plus prednisone rather than enzalutamide in COU-AA-302’s asymptomatic or mildly symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer setting without prior ARPI exposure, beyond comorbidities and tolerability?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One speaker prefers enzalutamide, with patient-specific exceptions"},{"id":"section-2","level":2,"title":"One speaker favors enzalutamide despite acknowledging cross-trial differences"},{"id":"section-3","level":2,"title":"Speakers describe a major advance, with analysis timing shaping their survival language"},{"id":"section-4","level":2,"title":"Speakers value delaying symptoms and chemotherapy, while one questions how quality of life was measured"},{"id":"section-5","level":2,"title":"Whether less prednisone is better remains unresolved in one exchange"},{"id":"section-6","level":2,"title":"One safety interview reassures, without removing the risks emphasized elsewhere"},{"id":"section-7","level":2,"title":"Speakers describe treatment opportunity, while one X account questions earlier-use economics"},{"id":"section-8","level":2,"title":"One X account interprets prior local therapy as reassuring context, not a causal intervention"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"A podcast and an X account distinguish serial ARPI use from other sequencing choices"},{"id":"section-11","level":3,"title":"Whether treatment adaptation can prolong usefulness remains exploratory"},{"id":"section-12","level":3,"title":"One case speaker favors a bone-directed combination; X accounts describe separate intensification and sequencing choices"},{"id":"section-13","level":3,"title":"One X account emphasizes low-resource dosing access without establishing dose equivalence"},{"id":"section-14","level":3,"title":"One X account raises a real-world benchmark gap without identifying its cause"},{"id":"section-15","level":3,"title":"One episode explores response biology without presenting a routine predictive test"},{"id":"section-16","level":3,"title":"One X account extrapolates across imaging-defined disease categories"},{"id":"section-17","level":2,"title":"Scope and coverage of the sources reviewed"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":7},{"id":"F4","shared_claims":3},{"id":"F7","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Survival"},{"findings":[{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T2","label":"Primary endpoint: Radiographic Progression-free Survival (rPFS)"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":7},{"id":"F7","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":1},{"id":"F7","shared_claims":3},{"id":"F11","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":4}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F5","shared_claims":5},{"id":"F6","shared_claims":13}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-14T11:30:43.253074Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-14T12:17:57Z","record_hash":"94f24b13cf4b1772da2f1d81c5509484db17764f6cfbe0fb190a1bc2df896873","release_hash":"b55fc20f9baf6d7817a6572753ca86076512ff46e10bd28b5a33895f4833d2cb","report_id":"erudio-nct00887198","run_id":"8e7b0fdf-584c-41b2-a7b6-83ff1ef8f9a2","schema_version":"5.0","slug":"cou-aa-302-nct00887198","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"One speaker reads COU-AA-302 as supporting abiraterone through chemotherapy deferral but would probably choose enzalutamide for simpler treatment, while considering abiraterone for high falls risk. A medical oncologist sees a clear survival advantage as reshaping care previously centered on docetaxel; the first speaker finds the final survival gain smaller than expected. That treatment preference is not demonstrated superiority: the cross-trial discussion cannot establish relative benefit, and prednisone's anticancer dose effect remains unresolved.","examples":[],"meta_description":"120 sources screened · 266 verified statements (19 from clinicians verified by NPI or staff page) from 37 sources · 11 findings. Updated Nov 14, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-14T12:17:57Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":120},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Not yet captured in this edition: a view on distinguishing newer androgen receptor inhibitors from first-generation agents when considering abiraterone alternatives in castration-resistant prostate cancer; a view on androgen receptor pathway inhibition versus chemotherapy in metastatic castration-resistant prostate cancer after androgen deprivation alone; a view on prednisone’s potential benefits and harms in interpreting abiraterone trial controls and cross-trial comparisons; a view on antiandrogen therapy’s place among systemic treatment options for metastatic castration-resistant prostate cancer; a view on crossover and secondary outcomes when weighing alternative therapy in chemotherapy-naive metastatic castration-resistant prostate cancer.","149 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 45 sources about other trials or topics are not included.","These sources are not a representative sample of HCP opinion. Source totals, reposts and nested relays cannot be interpreted as independent-clinician counts or consensus.","Several spoken passages cannot be assigned to a named participant. They are attributed to their episode or discussion and are not counted as separate people.","The PREVAIL comparison is incompletely represented, including crossover, subsequent-treatment, chemotherapy-delay, quality-of-life and skeletal-event context.","The available account of an ongoing prednisone analysis and suggested negative aspect does not fully support characterization of its evidence or ownership.","Coverage of comments about alternatives to ARPI monotherapy, later-line treatment options and earlier antiandrogen evidence is incomplete. The options described here should not be read as everything discussed in those exchanges.","No separate protocol was available. Full text was unavailable for the rPFS-biomarker and initial-Gleason-score papers, limiting assessment of their detailed methods and qualifications.","Discussion that does not name COU-AA-302 or uses different terminology may be missing. Absence from this edition does not establish absence from public discussion.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Cross-trial comparisons, historical controls, retrospective subgroups, early-phase research and individual patient experiences are preserved as such; none establishes head-to-head superiority or a validated new treatment-selection rule."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":2,"publication":15,"registry":0,"regulatory":0,"x_thread":15,"x_video":2,"youtube":3},"by_evidence_role":{"commentary":22,"context":5,"results":10},"count":37,"evidence_window":{"end":"2026-09-14","start":"2012-08-09"},"retrieval_snapshot":"2026-11-14T10:11:52.162527Z","timeline":[{"count":1,"week":"2012-W32"},{"count":1,"week":"2014-W21"},{"count":3,"week":"2014-W39"},{"count":1,"week":"2015-W05"},{"count":1,"week":"2015-W10"},{"count":1,"week":"2016-W04"},{"count":1,"week":"2017-W23"},{"count":1,"week":"2019-W15"},{"count":1,"week":"2022-W34"},{"count":1,"week":"2022-W35"},{"count":3,"week":"2023-W10"},{"count":1,"week":"2023-W16"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2025-W32"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W38"}],"undated_sources":15},"quote_policies":[{"id":"clinicaltrials:NCT00887198:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00887198:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00887198:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:23228172","quote_policy":"short_quote_link_out"},{"id":"pubmed:24075621","quote_policy":"short_quote_link_out"},{"id":"pubmed:24647231","quote_policy":"short_quote_link_out"},{"id":"pubmed:24787968","quote_policy":"short_quote_link_out"},{"id":"pubmed:25593303","quote_policy":"short_quote_link_out"},{"id":"pubmed:25601341","quote_policy":"short_quote_link_out"},{"id":"pubmed:25624432","quote_policy":"short_quote_link_out"},{"id":"pubmed:25829400","quote_policy":"short_quote_link_out"},{"id":"pubmed:25985882","quote_policy":"short_quote_link_out"},{"id":"pubmed:26609008","quote_policy":"short_quote_link_out"},{"id":"pubmed:27402060","quote_policy":"no_derivatives"},{"id":"pubmed:28939004","quote_policy":"short_quote_link_out"},{"id":"pubmed:34373138","quote_policy":"short_quote_link_out"},{"id":"pubmed:41324553","quote_policy":"short_quote_link_out"},{"id":"pubmed:42286315","quote_policy":"short_quote_link_out"},{"id":"openfda:413c645e-074d-4276-b39a-d83521077602:20261026","quote_policy":"short_quote_link_out"},{"id":"openfda:55aedced-d945-4bd2-9aa8-0f18b89a0e7f:20261109","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:54d3c0","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e0035b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1012008419048468481:fb58b671-ce81-423b-9b3e-759a2d36f801","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1117343986719416320:a2a84f50-3898-415b-93ac-3d9985a91ba2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1167435776667398145:c2823ffa-c9a9-4028-a5fb-d7487db817d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1202701109996994560:c3461e05-10e0-45e1-85de-8a75f5799881","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1415725393726816262:cb21830b-1e3d-4957-a276-e3cf640628bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1439587016056971267:116a1ec1-420b-4b61-8baf-bbee359c71a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1525043712568483840:69192033-330e-4c73-91ab-b31c9035545f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1525711883604328448:6e37c569-78f1-41bd-bfec-e101495d2aef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1526467892488830977:42f3966d-26c9-4150-93ac-7790a49b9a80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542104394530926592:adf404da-3730-47f4-b719-806805565318","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1562903315239038977:b2fb0015-9a95-4658-a1bd-8ca023bb24a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1564227378955489280:6aeb7b22-7206-44cb-bcdc-9a1d92aa9a1b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1567120760484790278:6cf81cb8-a471-4434-a13d-f6f8ad03730c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1628403480028413953:5a847652-bbda-4146-8c23-20bed7db619d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1633201348798988289:a5222209-e401-4458-b0c0-8dcfbc5dc6f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1633257093556760583:184e5e9d-0a25-4288-a0ff-fbd8a0c8b9e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1634618974905180160:ff0ff453-32e5-4695-a895-57553c434f4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1654867766363529218:87928b99-50ac-4f73-a7e7-62b1f4cfbcf6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1657392799153549313:57c0c162-22f5-4e8e-9876-dcbfbc0b090a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665079063176794114:0a1aea42-f673-4ee2-aa47-a17dc3b36353","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1668347491069091863:f171c89b-801d-4ba5-99d8-cd0ba3a8531d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1669117186906939395:50a567ba-57db-4d1e-826c-c470de742970","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1671132265756098560:d8361dd9-97aa-40ee-8c92-f3bbb6460acb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672052576236232704:c737f7f5-5790-4cb4-90f0-70db4a59ea5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1679883622319357952:85ecd69c-0be6-4642-8005-1b81f552a140","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1691147765395714048:c907ddbc-6460-42bf-b232-fffee6a11473","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1800220273788195324:bb10d72c-771c-46d0-a6e1-75e3ca1bd5e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840369171168710726:a4820421-2b91-4beb-90cc-8a20d74db15f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840371193083310519:3c0e186f-ed8b-4ed4-9343-e34f6c1f0081","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840402474366087377:1d9d70da-7bb4-40c4-9858-bdeb46e048eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867487052624761260:2f4795bb-1131-42cf-9ff4-8cb2e784f6bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1952743695897215388:68b99b53-1423-429b-879e-4f951448edae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960847768836092162:0db0858b-e576-4a1f-8155-30dd223b7ab6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2021574474248901023:78f82ca4-9ac9-49bf-8390-316d5880c230","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037205479944757422:4f97884f-7bef-4397-b20c-69b30bc783c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047659577383235722:8f3c0523-ddc0-42be-8a0e-9ea83ea52dc1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:212270193169285120:157f54ad-abf6-431a-86b1-c1a91049ed01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:212562354813153282:9e72e1ea-8397-4393-9e6b-f5bd06646532","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:235384867997773824:6a3d45b9-5f17-47e4-a1db-9c94f4f0c6b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:255037554406080512:f6778df5-ace6-4b77-87eb-91fc958e0eae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:278947498784088068:f7d96635-9d59-4fe3-8c91-b706e3f95133","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:286193909019844608:a1ef5067-dc53-4175-8914-5abc9922744a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:288114242417201152:6cdd4047-fcc7-455c-bfea-852d6d667c98","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:288480225698914306:cb36e7c8-d2eb-49fb-9069-d13206671ba8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:290461144534106113:eccda932-cb07-434e-af62-23405bbcb221","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:302688544529473537:53766aef-9d64-4b0d-937b-9d23e7ec0a56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:319972675642617856:e5323556-1760-452e-b76b-7dd6d3b0ca1e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:319988274645069825:652e9a60-4602-4c22-b338-fc0fdf3cf9cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:320990838417137667:4ecbc9b4-c713-43f6-b87d-0b3e77efb1d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:321250876079603714:d6e57b7c-d720-4de5-8183-a0d1d73a167a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:321783408428716032:649b1207-e52a-4fe0-ba51-89483cfdbcf6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:332588530465398784:a78b9aed-dbb7-46d5-86c8-59b1ba9732d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:332658172785459201:d7130bef-6311-4bbc-96b7-4db7a3f96f95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:334225487029235712:9652687e-ebda-4a1b-bfae-1bf31a3e43b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:340918057616674817:4bbfed4f-8b4f-414c-8498-f45a57eeeccc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:341197776513794049:c90f39dc-14f2-4428-a2ea-121d574c2e97","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:341640519975309313:26a91ac2-3ed1-47ce-8d5c-d25db9ab4b94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:406460853073223680:8d462808-1b7a-42ac-8b4e-7c29f95719db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:455760273404473344:bc990f9c-d39e-4f80-96c4-e21409d383a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:469204882373632000:9804c029-8f5f-4b15-9ea8-f9e2a4b24035","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:471359337487556608:81c3716c-4af7-41ab-9f26-8aba236e03fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:471359337491746816:91f6d508-f7c3-4177-b38f-bf88de5064a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:471359337852440576:acb47714-e027-4dce-b296-f2ef8ea04a1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516154034705924096:801cccd5-f307-4482-87cc-6d21e5788a8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516154799226896385:4abf6402-f862-4a23-abf6-af1d6fb9634b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516156086492356608:5f8ffb55-a38c-41b6-a13b-c59d2f1be986","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516157846527164416:3033e690-4853-4ead-9027-cae02efc5192","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516160540365053953:5501f519-050b-4588-b8b5-df30f163eb79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516594522403246081:36cad9f2-ee8d-4802-b082-152a677e6669","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516817480400900096:eb9191cf-aef3-4480-9e5f-852908fc1774","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516832766819074048:2c0947ed-cd4b-444a-87d3-fecf1bf91811","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516865454011199489:cd495e49-a770-43da-adb7-45642ba31e85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516876989836587008:8c74e9b9-f443-4246-8ce9-f1c571af8498","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516899801376370688:08d93641-75bf-4b3e-9212-8d998e3bcf1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516899811472060416:6bc37db6-9b82-4e6d-8da0-2df42049f84a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516903142600896512:d9e835ab-c2a2-453e-bc03-163bfd0aa546","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:516989407128064000:21a13bd7-1447-486c-b4a8-42681b413ba8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:517015389532733440:864e3bc6-6f2b-4e50-861d-ab6941b9b728","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:517145980349583361:80c251f7-71a8-4a6e-b30c-0acaa49ba65b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:527517400208404480:8b84d7de-4c0c-4a24-8325-ae370c99e152","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:530096934317723649:eceeee09-aab1-4886-934e-739ee545ba16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:530097046771212289:ab858307-3cc4-4567-95d2-821adb62ec68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:530361929865633793:e579b4a7-8048-44cd-8479-b1b800272a78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:532221610501996544:91445400-1416-45e3-8f18-0f50a24ba773","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:556007987262021632:0b859d66-8138-45c9-9d21-309a16cc8217","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:558909392209600512:c48046db-4141-44e3-b685-e203cd19ec0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:559875590795558913:116bd55b-da75-4888-9f02-4f678236d60d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:560611800434356224:f64367bd-5d8f-4e9c-924e-788620699b63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:560772190787104768:3e79fb6c-9a6c-4f16-b5c5-8114a9079fb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:561493044697247746:7691d7b7-a2f5-4d1d-9f02-037ea642bc15","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:563025012878499840:12993717-cc87-44de-b7af-ea71b41aa46e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:567288746253750272:9ba7d7a9-3111-4429-8267-9b4260deaaa7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:571126128410112000:dc103eee-64f5-4e14-989c-9934ce7fd188","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:571487510641172480:7be5e4c2-29bb-4eca-88fe-3b48e6045ed5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:571695127103733762:2a3d73dd-fbfe-41e6-9c0b-094a8968b9f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:575427247512903680:a1fbd02d-e49b-48f8-a01b-b0cdb332af44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:582920392576266240:9ece6543-5da0-4075-ad44-892e09dd7d17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:583419913626382336:b1082a36-e97b-42df-8fb4-952271e4d4f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:588385552879067136:377dc8a0-a994-4d47-9838-565cd4afcd2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:590241504591007744:8bb0ce9e-1bd2-438a-ace9-f643343ba027","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:603479020391530496:39046fba-01bb-4b1d-9ea2-f100b2d87875","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:692329482846244865:3b6c0f93-b384-4feb-8aae-1860d76011b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:709398505744302080:d99851b0-d727-44ee-918d-81158a7264ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:871567293070934016:3e387436-c95e-4965-91e9-567874689db1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:907164575447048193:89111179-d271-4cd9-87f4-3732ad185d49","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:940240167549497345:9b2994fc-66dc-48f6-b867-e51970ee4e10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:940316279843557376:f2cdc627-6a29-4ce2-9a7b-43dadbfb82c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:963103138902368257:5b011d28-b4d3-4aed-9ea9-d1dc1166b621","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:965028369560686592:a4556e1c-5b8e-47d0-8048-9206364045a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:968184336116797440:2d9226af-7375-4346-b027-7551174dc722","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:971445806514532356:d310c7b9-a47e-49a2-acf7-808ac883ac75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:975137416175550465:2fb4a322-4703-485d-b896-072aaee783c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:992417356898099200:44d06d63-444e-4f2f-a6e7-88a7eed3641c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1952743695897215388","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2099453705485513003","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NQ3Zl54L9fg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QszvgWfEhQM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:m-RA7rG5M6c","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":113,"x_video":2,"youtube":3},"by_evidence_role":{"commentary":120},"count":120,"evidence_window":{"end":"2026-09-14","start":"2012-06-11"},"retrieval_snapshot":"2026-11-14T10:11:52.162527Z","timeline":[{"count":2,"week":"2012-W24"},{"count":1,"week":"2012-W32"},{"count":1,"week":"2012-W33"},{"count":1,"week":"2012-W40"},{"count":1,"week":"2012-W50"},{"count":1,"week":"2013-W01"},{"count":3,"week":"2013-W02"},{"count":1,"week":"2013-W07"},{"count":3,"week":"2013-W14"},{"count":2,"week":"2013-W15"},{"count":2,"week":"2013-W19"},{"count":1,"week":"2013-W20"},{"count":2,"week":"2013-W22"},{"count":1,"week":"2013-W23"},{"count":1,"week":"2013-W48"},{"count":1,"week":"2014-W16"},{"count":2,"week":"2014-W21"},{"count":3,"week":"2014-W22"},{"count":5,"week":"2014-W39"},{"count":11,"week":"2014-W40"},{"count":1,"week":"2014-W44"},{"count":3,"week":"2014-W45"},{"count":1,"week":"2014-W46"},{"count":1,"week":"2015-W03"},{"count":1,"week":"2015-W04"},{"count":4,"week":"2015-W05"},{"count":1,"week":"2015-W06"},{"count":1,"week":"2015-W08"},{"count":3,"week":"2015-W09"},{"count":1,"week":"2015-W10"},{"count":1,"week":"2015-W11"},{"count":2,"week":"2015-W14"},{"count":1,"week":"2015-W16"},{"count":1,"week":"2015-W17"},{"count":1,"week":"2015-W22"},{"count":1,"week":"2016-W04"},{"count":1,"week":"2016-W11"},{"count":1,"week":"2017-W23"},{"count":1,"week":"2017-W37"},{"count":2,"week":"2017-W50"},{"count":2,"week":"2018-W07"},{"count":1,"week":"2018-W09"},{"count":1,"week":"2018-W10"},{"count":1,"week":"2018-W11"},{"count":1,"week":"2018-W18"},{"count":1,"week":"2018-W26"},{"count":1,"week":"2019-W15"},{"count":1,"week":"2019-W16"},{"count":1,"week":"2019-W35"},{"count":1,"week":"2019-W49"},{"count":1,"week":"2021-W28"},{"count":1,"week":"2021-W37"},{"count":1,"week":"2021-W38"},{"count":2,"week":"2022-W19"},{"count":1,"week":"2022-W20"},{"count":1,"week":"2022-W26"},{"count":1,"week":"2022-W34"},{"count":1,"week":"2022-W35"},{"count":1,"week":"2022-W36"},{"count":1,"week":"2023-W08"},{"count":3,"week":"2023-W10"},{"count":1,"week":"2023-W16"},{"count":1,"week":"2023-W18"},{"count":2,"week":"2023-W19"},{"count":1,"week":"2023-W22"},{"count":2,"week":"2023-W24"},{"count":2,"week":"2023-W25"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W33"},{"count":1,"week":"2024-W24"},{"count":3,"week":"2024-W39"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2024-W50"},{"count":2,"week":"2025-W32"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W38"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":87,"publication":138,"registry":0,"regulatory":0,"x_thread":20,"x_video":4,"youtube":17}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Zytiga"],"label":"abiraterone acetate","slug":"abiraterone-acetate"},{"brand_names":["Cortan","Delta-Dome","Deltasone","Fernisone","Liquid Pred","Meticorten","Orasone","Paracort","Prednicen-M","Rayos","Servisone"],"label":"prednisone","slug":"prednisone"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"COU-AA-302","aliases":["COU-AA-302","CR016927","Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer"],"brief_title":"Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Prostate Cancer"],"display_condition":"chemotherapy-naive metastatic castration-resistant prostate cancer","display_interventions":[["abiraterone acetate"]],"enrollment":{"count":1088,"type":"ACTUAL"},"interventions":[{"name":"Abiraterone acetate","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Prednisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT00887198","official_title":"A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2014-03-31","type":"ACTUAL"},"primary_endpoints":[{"description":"Overall survival is defined as the time from randomization to date of death from any cause.","measure":"Overall Survival","timeFrame":"From randomization (Day 1) up to end of study (Month 60)"},{"description":"The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\\>=) 2 new lesions compared to baseline was observed in less than (\\<) 12 weeks from randomization and was confirmed by a second bone scan taken \\>=6 weeks later showing \\>=2 additional new lesions (a total of \\>=4 new lesions compared to baseline), b) the first bone scan with \\>=2 new lesions compared to baseline was observed in \\>=12 weeks from randomization and the new lesions were verified on the next bone scan \\>=6 weeks later (a total of \\>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.","measure":"Radiographic Progression-free Survival (rPFS)","timeFrame":"From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)"}],"registered_date":{"date":"2009-04-23","type":"ESTIMATED"},"registry_last_updated":"2025-02-04","registry_url":"https://clinicaltrials.gov/study/NCT00887198","short_name":"COU-AA-302","short_name_basis":"canonical_name","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2009-04-28","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"CR016927","type":"sponsor_study_id"},{"domain":"Janssen Research & Development, LLC","id":"COU-AA-302","type":"other"},{"id":"2008-008004-41","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}